Actavis CEO and key strategist 1999 to 2008
Under Róbert Wessman’s leadership, Actavis became a leading force in the generic pharmaceutical industry.
Alvogen Executive Chairman and CEO 2009 - currently
As founder and CEO, Róbert Wessman has led Alvogen from being a small US-based contract manufacturing business to becoming a significant generic player in the regions it operates in. Wessman is currently the Chairman of Lotus Pharmaceuticals, an Alvogen company headquartered in Taiwan, a high-value generic pharmaceutical company covering CNS, CVS, oncology, women’s health, and anti-obesity drugs in tablets & hard/softgel capsules, for global markets.
Alvotech Founder and Chairman 2012 - currently
Alvotech is a biopharmaceutical player with a fully integrated R&D, API and fill and finish capabilities with a brand new state-of-the art facilities in Reykjavik, Iceland.
Leadership & track record
Companies led by Wessman have a collective annual average revenue growth rate of more than 60% (1999-2016). He has led over 50 strategic acquisitions and partnerships and established operations in over 60 countries around the globe. Wessman’s achievements have made him the subject of three Harvard Business Studies, titled “Róbert Wessman and the Actavis Winning Formula” (2008) and “Alvogen” (2015).